Activation profiles of opioid ligands in HEK cells expressing δ opioid receptors by Gharagozlou, Parham et al.
BioMed  Central
Page 1 of 8
(page number not for citation purposes)
BMC Neuroscience
Open Access BMC Neuroscience  2002,  3 x Research article
Activation profiles of opioid ligands in HEK cells expressing δ opioid 
receptors
Parham Gharagozlou1, Hasan Demirci1, J David Clark2 and Jelveh Lameh*1
Address: 1Molecular Research Institute, Mountain View, CA 94043, USA and 2VA Palo Alto Health Care System, Palo Alto, CA, USA
E-mail: Parham Gharagozlou - parhamgr@purisima.molres.org; Hasan Demirci - demircha99@hotmail.com; J Clark - djclark@stanford.edu; 
Jelveh Lameh* - jlameh@purisima.molres.org
*Corresponding author
Abstract
Background: The aim of the present study was to characterize the activation profiles of 15 opioid
ligands in transfected human embryonic kidney cells expressing only δ opioid receptors. Activation
profiles of most of these ligands at δ opioid receptors had not been previously characterized in vitro.
Receptor activation was assessed by measuring the inhibition of forskolin-stimulated cAMP
production.
Results: Naltrexone and nalorphine were classified as antagonists at δ opioid receptor. The other
ligands studied were agonists at δ opioid receptors and demonstrated IC50 values of 0.1 nM to 2
µM, maximal inhibition of 39–77% and receptor binding affinities of 0.5 to 243 nM. The rank order
of efficacy of the ligands tested was metazocine = xorphanol ≥ fentanyl = SKF 10047 = etorphine
= hydromorphone = butorphanol = lofentanil > WIN 44,441 = Nalbuphine = cyclazocine ≥ met-
enkephalin >> morphine = dezocine. For the first time these data describe and compare the
function and relative efficacy of several ligands at δ opioid receptors.
Conclusions: The data produced from this study can lead to elucidation of the complete activation
profiles of several opioid ligands, leading to clarification of the mechanisms involved in physiological
effects of these ligands at δ opioid receptors. Furthermore, these data can be used as a basis for
novel use of existing opioid ligands based on their pharmacology at δ opioid receptors.
Background
Opioid receptors belong to the large superfamily of G pro-
tein coupled receptors [1]. Three major types of opioid re-
ceptors (µ, δ and κ) have been cloned and each one is
associated with several physiological and behavioural
roles. The focus of the present work is the δ opioid recep-
tor. Delta opioid receptors play a modulatory role in anal-
gesia, hibernation, autonomic nervous system function,
neuroendocrine system function, mood driven behav-
iours and olfaction [2]. Thus, understanding the require-
ments for activation of δ opioid receptors can lead to
identification and design of novel drugs acting through
this receptor for treatment of various physiological prob-
lems.
While designing drugs with selectivity to a single receptor
can be a desirable approach in drug design, another ap-
proach may be to design drugs that act on more than one
receptor, but with differential activity on each receptor.
These would be drugs that act as an agonist at one receptor
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and as an antagonist or partial agonist at another receptor
type. The latter approach would be useful in situations
where the same receptor type that mediates the beneficial
effect of the drug also mediates the untoward effect [3]. In
this case interaction with another receptor type could re-
verse the unwanted effects associated with the activation
of the first receptor.
In the absence of comprehensive activation data for opio-
id ligands at δ opioid receptors, we set out to characterize
a set of fifteen opioid ligands for their activity in cells ex-
pressing only δ opioid receptors. These ligands were se-
lected based on our previous data showing that they
bound all three opioid receptors [4]. However, model tis-
sue studies [5] and in vivo studies [6] had suggested that
these ligands exhibited differential activation profiles at
the three opioid receptors. Thus the present study was de-
signed, (1) to describe the activation profiles of a set of
opioid ligands not previously defined at an isolated cell
system expressing only δ opioid receptors, and (2) to com-
pare the relative efficacies and potencies of these ligands
to the strongest ligand in the set, metazocine, to the com-
mon opioid analgesic, morphine and to the endogenous
δ opioid ligand, met-enkephalin.
In this study, the activity of δ opioid receptor was meas-
ured by assessing the levels of inhibition of forskolin-
stimulated cAMP production in the presence of various
opioid ligands. It has been reported that δ opioid recep-
tors couple more efficiently to adenylyl cyclase system
than to Ca2+ channels [7]. This evidence supports the use
of cAMP system for assessing the activity of these recep-
tors. Moreover, cAMP has been implicated in playing a
role in the analgesic effects mediated through δ opioid re-
ceptors [8,9]. Human embryonic kidney cells stably ex-
pressing mouse δ opioid receptors were used to
characterize the activation profiles of opioid ligands in
this study. The results describe the activity of a set of lig-
ands not previously characterized at δ opioid receptors.
The results obtained from this study will serve to define
the relative efficacies and potencies of a set of opioid lig-
ands compared to one another and differentiate between
the full and partial agonists at δ opioid receptors.
Results
Receptor activation
All ligands used (Table 1) were non-peptide ligands select-
ed for lack of selectivity for different opioid receptors. In
the majority of cases the data were reproducible and inter-
experimental variability was small (Figure 1). Thus the
data from several experiments were normalized to the top
of the fitted curve (no ligand, forskolin alone), the results
of several experiments pooled and a new fitted curve con-
structed (Figure 2). The IC50 values in Table 1 are the re-
sults of the pooled normalized data from 3 or more
experiments carried out in duplicate.
Two ligands, nalbuphine and naltrexone were categorized
as antagonists. All other ligands studied showed a robust
inhibitory effect on the forskolin stimulated cAMP pro-
duction (Table 1). The rank order of efficacy of the ligands
tested was metazocine = xorphanol ≥ fentanyl = SKF
10047 = etorphine = hydromorphone = butorphanol =
lofentanil > WIN 44,441 = Nalbuphine = cyclazocine ≥
met-enkephalin >> morphine = dezocine. Statistical anal-
ysis showed that most of the agonists tested had efficacies
that were not significantly different from that of the en-
dogenous ligand met-enkephalin. The only exceptions
were the highly efficacious ligands fentanyl (P < 0.05),
metazocine (P < 0.001) and xorphanol (p < 0.001).
The potencies for the different ligands ranged from 0.2 –
2039 nM. The most potent ligands studied, as measured
by the lowest IC50 values (Table 1), were etorphine, cycla-
zocine, lofentanil, and xorphanol with IC50's of less than
10 nM. The other ligands, met-enkephalin, WIN 44,441,
hydromorphone and Butorphanol, exhibited potencies of
10–100 nM; metazocine and SKF 10047, 100–200 nM,
and nalbuphine, dezocine and morphine, 400–1000 nM.
The least potent ligand was fentanyl with an IC50 of about
Figure 1
Reproducibility of dose response curves for xorpha-
nol at δ opioid receptors. This graph represents inter-
experimental variability for dose response curves. Three
independent experiments were carried out in duplicate. Var-
ying concentrations of xorphanol were used to determine
the potency and efficacy of xorphanol in inhibiting the effect
of 5 µM forskolin in producing cAMP, as described under
methods. Maximal cAMP levels were in the range of 400–
1000 pmole/well. Data have been normalized as described
under methods. Error bars represent standard error of the
mean of duplicate measurements for each point.
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2 µM. The rank order of potency of these ligands was; etor-
phine>lofentanil≥cyclazocine=xorphanol>met-enkepha-
lin> Win
44,441=hydromorphone≥butorphanol>metazocine=SKF
10047> dezocine≥ nalbuphine>morphine>fentanyl.
Figure 2 depicts dose-response curves of a representative
set of ligands. Etorphine and lofentanil are shown as ex-
amples of two very efficacious and highly potent ligands.
SKF 10047 is representative of a very efficacious ligand
with intermediate potency. Finally, fentanyl is shown as
an example of a ligand with very low potency, which is
nevertheless very efficacious if high enough concentra-
tions are used.
Receptor binding
Human embryonic kidney (HEK) cells were transfected to
express mouse δ opioid receptors. These cells do not ex-
press any endogenous δ opioid receptors, as they lack
binding of the radioactive tracer [3H]-DPDPE (data not
shown), thus they serve as a good system for the expres-
sion of opioid receptors. A single clone of HEK cells, sta-
bly expressing 1925 ± 425 fmole/mg protein δ opioid
receptors, was selected for this study. The Kd for [3H]-DP-
DPE in these cells was 0.65 ± 0.27 nM. These cells were
used to characterize the activity of fifteen opioid ligands in
inhibiting forskolin-stimulated cAMP production.
Ligands that showed very low potencies or low enough ef-
ficacies to be tested for antagonistic effect were further
characterized for their binding affinities at δ opioid recep-
tors. All ligands studied exhibited Ki values in nanomolar
range. The rank order of affinity of the ligands was xorph-
anol > Win 44,441> nalorphine > morphine ≥ nalbu-
phine > fentanyl (Table 2). The rank order of affinity
agrees with the rank order of potency of these ligands in
inhibiting forskolin-stimulated cAMP production.
Discussion
Ligands acting at δ receptors can induce antinociception
both spinally and supraspinally [10–12], thus identifying
ligands that activate δ opioid receptors and determining
their physiochemical characteristics is essential to under-
standing opioid receptor pharmacology and physiology.
There is evidence suggesting that δ selective opioid ligands
do not cause changes in respiratory parameters [13]. Thus,
suggesting that designing specific ligands that act at δ opi-
oid receptors may be useful in formulating analgesics
without the side effect of ventilatory depression. Yet, some
selective δ ligands have been shown to be ineffective anti-
nociceptive agents when given systemically [14–16]. The
reason for this ineffectiveness is not clear. Still, other re-
ports, have suggested that opioid ligands with agonistic
effect at µ opioid receptors and antagonistic effect at δ opi-
oid receptors are potentially useful analgesics [3,17,18].
These latter results advocate that the key to designing opi-
oid ligands with optimal analgesia and minimal side ef-
fects may be in the design of ligands that act on more than
one receptor type, but activate each receptor differently.
Thus, it is useful to identify opioid ligands with differen-
tial activation profiles and characterize their physiological
effects (analgesic and unwanted effects). Prior to the de-
sign of any novel drugs based on this approach, it is nec-
essary to clearly understand how the known nonselective
opioid ligands act at δ opioid receptors. Such information
can not only help explain some of the paradoxical behav-
ioural data of these ligands, but it can also explain the in-
teraction of each ligand with a single receptor involved in
modulation of the pain pathways. The present data serve
to define the mode of action of a set of opioid ligands at δ
opioid receptors and will help explain the physiological
effect of these ligands. Moreover, since δ opioid receptors
have been reported to exert a physiology indicative of reg-
ulatory effects on hemodynamic balance and cardiac
function as well as hibernation, a better understanding of
δ receptor pharmacology can lead to possible novel uses
of δ ligands independent of analgesia.
Figure 2
Dose response curves of representative ligands on δ
opioid receptors Varying concentrations of opioid ligands
were used to determine the potency and efficacy of each lig-
and in inhibiting the effect of 5 µM forskolin in producing
cAMP, as described under methods. Maximal cAMP levels
were in the range of 400–1000 pmole/well. Data presented
are the average data from 2 or more experiments carried
out in duplicate. Data have been normalized as described
under methods. Error bars represent standard error of the
mean of the normalized data. () Etorphine, () Lofentanil,
(▼ ) SKF 10047 and () Fentanyl.
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The present study was designed as one of the steps in de-
fining the detailed pharmacology of a set of non-selective
opioid ligands and aimed at defining the activation pro-
files of these ligands at a well-defined system expressing
only δ opioid receptors. The use of such a system is essen-
tial for understanding the mode of action of ligands at a
specific receptor. Such data can then be used to interpret
the findings from more complex settings, such as in vivo
studies, where multiple opioid receptor types are ex-
pressed.
The data presented in this report agree with available pub-
lished data, thus establishing that the methods used were
valid and could be successfully used to provide useful data
for previously uncharacterised ligands. For example, as re-
ported, etorphine [19] and lofentanil [20] were shown to
be highly potent and efficacious at δ opioid receptors.
Comparison of the efficacies of the set of agonists in this
study to that of the endogenous ligand, met-enkephalin,
showed that all were full agonists. Moreover, fentanyl,
metazocine and xorphanol could be considered "super ag-
onists" at delta receptors based on having efficacies signif-
icantly greater than met-enkephalin. This observation
suggests that in situations where the endogenous ligand is
present (such as in a stressed animal), it is possible to
achieve further activation of δ opioid receptors by the ap-
plication of one of these ligands. Moreover, the efficacies
of the above "super agonists" were comparable to that of
δ selective ligands such as SNC80 and BW373U86. Based
on previous reports, maximum inhibitory effect of SNC-
80 in transfected δ opioid receptors is 71 ± 5% [21] and
94 ± 2% [22] with IC50 values of 15 and 6.3 nM respec-
tively. The maximum effect of BW373U86 has been re-
ported to be 70 ± 9% with IC50 of 0.9 nM [21]. Some
ligands that exhibited very low potencies in this study,
such as fentanyl or metazocine, were amongst the most ef-
ficacious ligands tested suggesting that these ligands are
capable of maximally activating δ opioid receptors. Thus,
different concentrations of these ligands can be used to
achieve various physiological effects based on the phar-
macological properties of these ligands on other opioid
receptors.
Fentanyl is a synthetic opioid ligand belonging to the phe-
nylpiperidine family of ligands. Based on receptor bind-
ing assays, fentanyl has an affinity for µ opioid receptors,
that is 100–1000 fold higher than that for δ opioid recep-
tors [23,24]. However, no published activation data for
fentanyl at δ opioid receptors was available. In vivo, fenta-
nyl is a strong analgesic agent in pharmacological doses
due to its interaction with µ opioid receptors [19]. How-
ever, at higher toxic doses it shows general opioid toxicity
symptoms in addition to muscular rigidity, which are re-
versible by naloxone. Muscular rigidity of fentanyl has
been suggested to occur via several mechanism involving
glutamatergic pathways [25], serotonergic system [26] as
well as noradrenergic system [27,28]. One other potential
Table 1: Activation Profile of Opioid ligands in HEK-δ Cells
LIGAND IC50 ± SEM (nM) Max Inhibition %
Butorphanol 61 ± 12 64 ± 4$
Cyclazocine 6 ± 35 3  ± 2**
Dezocine 477 ± 152 39 + 8
Etorphine 0.2 ± 0.1 67 ± 3$$
Fentanyl 2039 ± 554 71 ± 7$$ #
Hydromorphone 54 ± 31 65 ± 5$
Lofentanil 0.8 ± 0.4 62 ± 7$
Metazocine 159 ± 70 77 ± 4$$
Met-enkephalin 22 ± 17 49 ± 6##
Morphine 1101 ± 614 39 ± 4**
Nalbuphine 545 ± 378 55 ± 7*
Nalorphine Antagonist
Naltrexone Antagonist
SKF 10047 184 ± 121 68 ± 9$$
WIN 44,441 40 ± 25 54 ± 6*
Xorphanol 8 ± 27 6  ± 4$$ ##
Inhibitory effect of opioid ligands on Forskolin-stimulated Adenylyl Cyclase activity was measured as described under Materials and Methods. Data 
for IC50's represent the mean ± SEM obtained from two or more experiments carried out in duplicate. Maximum inhibition is the mean ± SEM of 
maximum inhibition obtained from a best fit curve as described under "Materials and Methods" (** = P < 0.001, * = P < 0.05 compared to Metazo-
cine), ($$ = P < 0.001, $ = P < 0.05 compared to morphine), (## = P < 0.001, # = P < 0.05 compared to met-enkephalin).BMC Neuroscience 2002, 3 http://www.biomedcentral.com/1471-2202/3/19
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pathway may be via regulation of dopaminergic system as
suggested before [29] possibly via δ opioid receptor sys-
tem as explained here. It has been reported that stimula-
tion of δ opioid receptors can cause inhibition of
dopamine release in striatal pathways, resulting in muscu-
lar rigidity [19]. The present report shows that although
fentanyl has low affinity and low potency at δ opioid re-
ceptor, it is highly efficacious at these receptors. Thus, at
high fentanyl concentrations δ opioid receptors can also
be fully activated possibly leading to the inhibition of
dopamine release and the resultant muscle rigidity. So the
data presented can serve to describe the mechanism of ac-
tion and physiological observations after application of
drugs in vivo. Based on the present data, a distinct effect of
morphine compared to fentanyl can be observed at δ opi-
oid receptors. While fentanyl is a full agonist at δ opioid
receptors, morphine is only a partial agonist. Thus, al-
though both these drugs can activate δ opioid receptors
with low potency, at high concentrations morphine can-
not stimulate δ receptor as effectively as fentanyl. Thus,
fentanyl, but not morphine, can elicit physiological
changes that are mediated by activation of δ opioid recep-
tors.
A different scenario holds true for the two ligands, xorph-
anol and WIN 44,441. Both these ligands have high affin-
ities and potencies at δ opioid receptors with xorphanol
being very efficacious at δ opioid receptors. At µ opioid re-
ceptors, however, the activation profiles of these ligands
are different. While both these ligands bind with high af-
finities (less than 1 nM) to µ opioid receptors, WIN
44,441 acts as an antagonist at µ opioid receptors and xor-
phanol is a very weak agonist at µ opioid receptor
(Gharagozlou et al. unpublished results). Thus these lig-
ands can be useful in clinical applications where activa-
tion of δ opioid receptors needs to be combined with a
weak action or an antagonistic action at µ opioid recep-
tors. Such an application can be very important due to the
unique physiology of δ opioid receptors. Studies such as
presented here can serve to provide the data necessary for
application of opioid ligands in such unique settings.
Moreover, until now the activity of xorphanol at δ opioid
receptors had not been described. This ligand had been
described as a mixed agonist-antagonist opioid ligand
[30,31] with agonistic activity at κ opioid receptors [32].
Overall very little work has been done on xorphanol and
little is known about it except that it is an orally active an-
algesic with limited physical dependence liability [30].
Thus the present report describing its activity at δ opioid
receptors provides useful data on this ligand.
Nalorphine, has been previously categorized as a "mixed
agonist/antagonist" ligand [6]. These are ligands that are
believed to act as an agonist at κ and as an antagonist at µ
opioid receptors. No published in vitro data was available
for the activation profile of this ligand at δ opioid recep-
tors. In this study nalorphine was shown to be an antago-
nist at δ opioid receptor with a moderate binding affinity.
Such a moderate affinity makes it possible for nalorphine
to antagonize the effect of other ligands or the endog-
enous ligand (like met-enkephalin) at δ opioid receptors
while possibly acting as an agonist at other opioid recep-
tors. Based on the regulatory role of δ opioid receptors
such applications may be numerous. Data similar to the
one presented in this report, will open the door for novel
applications of these ligands in the treatment of various
ailments.
Conclusions
The present study was designed to characterize the activa-
tion profiles of a set of opioid ligands in cells expressing
only δ opioid receptors. These ligands had not been previ-
ously characterized at δ opioid receptors. The data pro-
duced from this study can be used to achieve several goals.
(1) These data can lead to elucidation of the complete ac-
tivation profiles of these ligands, leading to clarification
of the mechanisms involved in physiological effects of
these ligands at δ opioid receptor. (2) These data can be
used as a basis for novel use of existing opioid ligands
based on their pharmacology at δ opioid receptors. (3)
These in vitro data can be utilized to define the physio-
chemical features of the ligands defining agonism and an-
tagonism at δ opioid receptors, leading to design and
discovery of novel opioid analgesics. (4) In combination
with in vivo data characterizing analgesic and unwanted
effects of these ligands, the in vitro data can be used to
identify the activation profile of the ideal opioid analgesic
that has minimal side effects. Such information, com-
bined with the knowledge on the physiochemical charac-
teristics of the agonists and antagonists at each receptor,
will lead to the design of novel opioid analgesics with
minimal side effects.
Table 2: Binding Profile of Opioid ligands in HEK-δ cells
LIGAND AFFINITY Ki (nM)
DPDPE 0.7 ± 0.3
Fentanyl 242.5 ± 102.5
Morphine 68.5 ± 19.5
Nalbuphine 77 ± 8
Nalorphine 38.5 ± 4.0
WIN 44,441 2.6 ± 0.9
Xorphanol 1.0 ± 0.2
Competition binding assays were carried out in cell homogenates of 
HEK-δ cells as described under Methods. Data represent mean ± 
SEM. of Ki values from two or more independent experiments carried 
out in triplicate.BMC Neuroscience 2002, 3 http://www.biomedcentral.com/1471-2202/3/19
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Methods
Cell culture
Human Embryonic Kidney (HEK) 293 cells were main-
tained in D-MEM/F-12 (Dulbecco's Modified Eagle's Me-
dium: Nutrient Mixture F-12 1:1 mixture), supplemented
with 10% (v/v) fetal calf serum (FCS), 200 µg/ml G-418
(Geneticin®) in a humidified incubator with 5% CO2 and
95% air, at 37°C. The incubation medium was changed
every 3–4 days. Once a week, cells were re-plated at 20%
density into 75-cm2 tissue culture flasks.
Transformation of δ opioid receptors and isolation of sta-
ble cells
Stably transfected HEK cells were developed as described
previously [33]. HEK 293 cells were transfected with the
cDNA for mouse δ opioid receptor in the pCI-neo® vector.
The mouse δ cDNA was obtained in the vector pCMV (a
generous gift from Dr. Graham Bell, University of Chica-
go). The 1.2 kb coding sequence of the receptor was sub-
cloned into pCI-neo®  mammalian expression vector
(Promega, Madison, WI) using the restriction sites EcoRI
and Sal I. HEK 293 cell were transfected with the vector us-
ing the lipofectin® reagent (Life Technologies, Rockville,
MD). Stable clones were selected using 400 µg/ml Ge-
neticin®. Single clone were picked and tested for expres-
sion of δ opioid receptor by binding assay. One clone
expressing 1925 ± 425 fmoles/mg protein, as assessed by
[3H]-DPDPE binding, was propagated for use in this
study.
Binding assays
Saturation binding assays were carried out for [3H]-DP-
DPE in HEK cells as described previously [34]. Crude cell
homogenate (20–25 µg of per assay tube) was used and
incubation was in 50 mM Tris HCl, pH 7.4 at room tem-
perature for 2 hours. The assay was terminated by rapid
filtration through Whatman GF/B filters using a FilterMa-
te cell harvester (Packard Instruments) followed by three
washes, 4 ml each, with ice cold buffer. Radioactivity re-
tained on the filters was measured using Microscint 0 in a
TopCount liquid scintillation counter (Packard Instru-
ments). Competition binding assays were carried out in
crude membrane homogenate of HEK-δ cells. Binding was
carried out in 250 µl volume of 50 mM Tris HCl buffer,
pH 7.4 in the presence of 0.5–1 nM [3H]-DPDPE and in-
creasing concentrations (24–32 different concentrations)
of unlabeled ligand. Incubation and binding were as de-
scribed above. Binding data were analyzed using the Af-
finity Analysis Software as described before [34,35]. For
preparation of crude membrane homogenate, confluent
cultures of HEK-δ cells were harvested using phosphate
buffered saline. Following centrifugation at 700 ×g, the
cell pellet was resuspended in ice-cold 50 mM Tris HCl
buffer pH 7.4 at about 107cell/ml, and homogenized us-
ing a polytron at setting 6 for 10 seconds. The cell ho-
mogenate was stored in aliquots at -86°C until use.
Protein content of the cell homogenate was determined
using Bio-Rad protein assay reagent (Bio-Rad, Hercules,
CA).
Whole cell adenylyl cyclase assays
Inhibition of Forskolin stimulated cyclic AMP (cAMP)
production by exposure to increasing concentrations of
agonists were evaluated in intact cells. Exponentially
growing HEK-δ cells were harvested and resuspended in
serum free DMEM/F12 medium. Cells were plated in 96
well microtiter plates at 5 × 104 cells/well in 100 µl vol-
ume. To each well, phosphodiesterase inhibitor 3-iso-
butyl-1-methylxanthine (IBMX) was added to a final
concentration of 100 µM, followed by addition of ago-
nists at different concentrations and incubation at 37°C.
Following 15 minutes incubation, forskolin was added to
each well to a final concentration of 5 µM followed by an-
other incubation for 15 min at 37°C. The final reaction
volume was 200 µl. The reaction was terminated by aspi-
ration of the medium and addition of 200 µl lysis buffer
from the Biotrak™ cAMP Enzyme Immunoassay kit from
Amersham Pharmacia Biotech (Buckinghamshire, Eng-
land). The rest of the assay followed the protocol provided
with the kit. Actual amount of cAMP was determined for
each sample in comparison to a standard curve of known
amounts of cAMP provided in the cAMP kit, as described
in the kit protocol.
Agonism
Agonistic activity of opioid ligands was assessed by meas-
uring the inhibitory effect of the ligands on forskolin-
stimulated cAMP accumulation. Data from each experi-
ment were normalized to the top of the curve (no ligand,
100%), expressed as percent inhibition of forskolin-stim-
ulated cAMP accumulation and were fit to a sigmoidal
function by using one site competition function as de-
scribed below. The efficacy of each ligand was defined as
percent inhibition of forskolin stimulated cAMP produc-
tion compared to no ligand levels (0% inhibition, 100%
cAMP production).
Antagonism
Compounds with very little in vitro agonistic activity
(<20% inhibition of cAMP production) for which the
dose response curves could not be fitted, were tested for
antagonism. Antagonists were identified as ligands that
were able to repeatedly block the inhibitory effect of 1 nM
etorphine on forskolin stimulated cAMP production. In
these assays, antagonist was added to the cells along with
IBMX. After 15 minutes of incubation, the agonist was
added and the cells were incubated with both ligands for
an additional 10 minutes. After addition of forskolin, the
cells were incubated for 15 additional minutes. The rest of
the assay was as described above.BMC Neuroscience 2002, 3 http://www.biomedcentral.com/1471-2202/3/19
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Curve fitting
The analysis of ligand activity was performed using PRISM
software (GraphPad Software, Inc. San Diego, CA). A
computer-generated "best fit" of non-linear regression
data was used to provide estimate of IC50. Dose response
data generated by cAMP enzyme immunoassay (EIA) sys-
tem were fitted with the one site competition function.
Data processing
Data from each dose response curve were normalized to
the top of the respective curve. The normalized data from
multiple dose response curves were combined and a new
dose response curve was fitted to the combined data and
maximal inhibition was determined for the combined da-
ta. IC50 values presented are the mean ± SEM of IC50 val-
ues from 2–3 independent experiments.
Drugs used
Forskolin, fentanyl, IBMX, hydromorphone, and naltrex-
one were obtained from Sigma-Aldrich (St. Louis, MO),
nalbuphine and met-enkephalin were obtained from RBI
(Natik, MA), cyclazocine, etorphine, metazocine, mor-
phine, nalorphine, and SKF 10047 were obtained from
National Institute of Drug Abuse (Bethesda, MD), lofen-
tanil was obtained from Janssen Pharmaceutical Inc. (Ti-
tusville, NJ), Dezocine was obtained from Wyeth
Laboratories (Philadelphia, PA), Win 444,441 was ob-
tained from Sterling Winthrop Pharmaceutical and Xor-
phanol was obtained from Miles Inc. Pharmaceutical
Division (West Haven, CT). All tissue culture reagents
were purchased from Life Technologies (Rockville, MD).
DPDPE was obtained from Peninsula Laboratories (San
Carlos, CA), and [3H]-DPDPE was from Multiple Peptide
Systems (San Diego, CA). All other reagents were of ana-
lytical grade from standard commercial sources.
All ligands used were prepared as 10 mM stock solutions
in water except WIN 44,441, which was 5 mM. All ligands
were dissolved in distilled water except cyclazocine, dezo-
cine, etorphine, which were dissolved in 100% ethanol.
For the drugs dissolved in ethanol, the final concentration
of ethanol was <0.01% which had no affect on the assays
performed.
Statistical analysis
Maximal inhibitory effect of each ligand was compared to
the levels of maximal inhibition by met-enkephalin,
metazocine and morphine using ANOVA analysis with
Dunnett's multiple comparison as post test using PRISM
software (GraphPad Software, Inc. San Diego, CA). Signif-
icant difference between the inhibitory effects of two lig-
ands was determined whenever p < 0.05.
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